This warehouse cannot ship to United States of America, United Kingdom, Canada, Austria, Australia, New Zealand, Malta, Czech Republic, Ireland, Switzerland, Finland, Sweden, Norway, Estonia and Denmark.
DO NOT place orders if you are based in these countries!
Respectfully,
OSGear Team
Tirzepatide Pen - Hilma Biocare
ACTIVE HALF-LIFE approximately 5 days (117–120 hours)
DOSAGE 2,5 to 15 mg
MANUFACTURER Hilma Biocare
WAREHOUSE 🇪🇺 EU Warehouse 3
SUBSTANCE
Tirzepatide,
Indication
Treatment of type 2 diabetes mellitus and weight loss. Tirzepatide is used to improve glycemic control in combination with diet and exercise.
Mechanism of Action
Tirzepatide has a higher affinity for GIP receptors than for GLP-1 receptors, and this dual agonist action provides a more pronounced reduction in hyperglycemia compared to a selective GLP-1 receptor agonist. Tirzepatide mimics the action of natural GIP on the GIP receptor. At the GLP-1 receptor, tirzepatide preferentially forms cAMP (a messenger involved in the regulation of glycogen, sugar, and lipid metabolism) rather than attracting beta-arrestin. This combination of its preference for the GIP receptor and the specific signaling properties of GLP-1 increases insulin secretion. Tirzepatide increases levels of both adiponectin and adipokine, which are involved in the regulation of both glucose and lipid metabolism, with a maximum increase of 26% from baseline after 26 weeks at a dose of 10 mg.
